Drugs / CD147-CART
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04045847 | May 2019 → Oct 2020 | antigen defined by monoclonal antibody T87, glioblastoma | Xijing Hospital | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03993743 | May 2019 → Oct 2020 | hepatocellular carcinoma | Xijing Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD147-CART | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04045847 ↗ |
| Modality | Cell therapy | “CAR-T cells” NCT03993743 ↗ |
| Route | Other | “by hepatic artery infusion” NCT03993743 ↗ |